{"entity":{"id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","aka":[],"tldr":"CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.","summary":"Camurus of Lund built CAM2029 on its FluidCrystal lipid depot so that octreotide can be given as a small subcutaneous self-injection rather than the intramuscular Sandostatin LAR. The phase 3 SORENTO trial in advanced gastroenteropancreatic neuroendocrine tumours met its primary endpoint of progression-free survival against octreotide LAR or lanreotide, and the company has filed in Europe and the United States; it is approved for acromegaly as Oczyesa in some markets.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of CAM2029 (octreotide subcutaneous depot)","url":"https://clinicaltrials.gov/search?intr=CAM2029%20(octreotide%20subcutaneous%20depot)"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["endocrine-therapy"],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05050942"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"modality":"Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot","mechanism":"Octreotide, a somatostatin analogue, released for a month from a lipid depot that forms under the skin after a small ready-to-use injection.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cam2029/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"trial":[{"id":"nct05050942","kind":"trial","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","route":"/trials/nct05050942/"}]}}